EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Cash from Financing Activities (2011 - 2026)

EyePoint (EYPT) posted Cash from Financing Activities of -$2.6 million for Q1 2026, down 101.57% sequentially from $167.0 million in Q4 2025, and down 174.87% YoY from $3.5 million in Q1 2025.

Analysis

EyePoint (EYPT) Cash from Financing Activities (2011 - 2026) Analysis & Trends

EyePoint has reported Cash from Financing Activities for 16 years, with the latest figure at -$2.6 million in Q1 2026.

  • Quarterly Cash from Financing Activities fell 174.87% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.0 million (up 5.54% YoY) and the FY2025 annual result came in at $173.6 million, up 5.87% from the prior year.
  • Cash from Financing Activities fell to -$2.6 million in Q1 2026 per EYPT's latest filing, from $167.0 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $218.5 million in Q4 2023 and troughed at -$36.7 million in Q2 2023.
  • A 5-year average of $30.7 million and a median of $115000.0 in 2024 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 376798.28% in 2023, down 13181.88% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$58000.0 in 2022, then surged by 376798.28% to $218.5 million in 2023, then tumbled by 30.57% to $151.7 million in 2024, then increased by 10.07% to $167.0 million in 2025, then plunged by 101.57% to -$2.6 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.6 million, $167.0 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 19.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 19.99 Mn
Mar 31, 2026 -2.61 Mn
Dec 31, 2025 166.96 Mn
Sep 30, 2025 7.40 Mn
Jun 30, 2025 238,000.00
Mar 31, 2025 -951,000.00
Dec 31, 2024 151.69 Mn
Sep 30, 2024 11.89 Mn
Jun 30, 2024 329,000.00
Mar 31, 2024 115,000.00
Dec 31, 2023 218.49 Mn
Sep 30, 2023 10.36 Mn
Jun 30, 2023 -36.66 Mn
Mar 31, 2023 -5.12 Mn
Dec 31, 2022 -58,000.00
Sep 30, 2022 92,000.00
Jun 30, 2022 -276,000.00
Mar 31, 2022 -448,000.00
Dec 31, 2021 108.52 Mn
Sep 30, 2021 -2,000.00